Drostanolone enanthate is an ester of drostanolone. Drostanolone is indicated in postmenopausal women with recurrent breast cancer, in combined hormone therapy. Drostanolone causes retention of nitrogen, potassium, and phosphorus; increases protein anabolism; and decreases amino acid catabolism.

The antitumor activity of drostanolone appears related to reduction or competitive inhibition of prolactin receptors or estrogen receptors or production.

Drostanolone enanthate 200 USP injection provides drostanolone enanthate, a potent androgenic steroid that has similar characteristics of dihydrotestosterone. Drostanolone is incapable of aromization and therefore it doesn’t convert into oestrogen. Both drostanolone’s anabolic and androgenic activity is far greater than methyl testosterone. The esterification of the 17-beta-hydroxyl group increases the duration of the action of drostanolone. Drostanolone esters in oil injected intramuscularly are absorbed slowly from the lipid phase, thu